Natera and Susan G. Komen Announce National Partnership to Accelerate Progress Against Breast Cancer
AUSTIN, Texas, August 28, 2026--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced a national partnership with Susan G. Komen®, the world’s leading breast cancer organization. Together, the organizations aim to accelerate breast cancer awareness and education, including efforts to increase understanding of MRD. Natera’s SignateraTM MRD test is supported by more than 185 peer-reviewed publications across multiple cancer types, including b
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.